Tiffany Traina, MD, FASCO
Articles by Tiffany Traina, MD, FASCO
112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
ByRebecca Dent, MD,Zhimin Shao,Peter Schmid, MD,Javier Cortés, MD,David W. Cescon,Shighira Saji,Kyung Hae Jung,Thomas Bachelot,Shouman Wang,Gul Basaran,Yee Soo Chae,Rofhiwa Mathiba,Shin-Cheh Chen,Agostina Stradella,Nicola Battelli,Naoki Niikura,Kechen Zhao,Petra Vukovic,Michah Maxwell,Tiffany Traina, MD, FASCO 
Panel Reflections and Future Directions in Breast Cancer Care
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how the expanding volume of clinical data—both positive and negative—is increasing treatment complexity while reinforcing the need for individualized, patient-centered decision-making.
Toxicity Management, Monitoring, and Quality-of-Life Concerns
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how toxicity monitoring and quality-of-life considerations must be adapted as potent therapies move into earlier-line and curative-intent settings.
High-Risk Populations, Patient Selection, and Advancements in Maintenance Therapy – Insights from Her2Climb05
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how identifying high-risk subgroups enables more precise selection of maintenance therapies that maximize progression-free survival while accounting for biomarker differences.
Optimizing HER2-Positive Disease Management: Neoadjuvant, Adjuvant, and Maintenance Advances
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how emerging neoadjuvant and adjuvant data in HER2-positive breast cancer are challenging traditional standards and supporting earlier use of highly effective agents.
Antibody Drug Conjugates in Hormone Receptor Positive Disease – ASCENT-07 and Beyond
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how results from antibody-drug conjugate trials, including those that fail primary endpoints, provide critical insights for refining sequencing strategies in hormone receptor–positive disease.
Post-CDK4/6 Endocrine Strategies and the evERA Trial
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how post-CDK4/6 endocrine strategies increasingly rely on molecular profiling to guide therapy selection and optimize benefit in resistant disease.
EMBER-3 and Progress in ESR1-Mutant Disease
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how data from recent ESR1-mutant disease trials are influencing interpretation of survival end points, regulatory expectations, and real-world adoption of oral SERDs.
Guideline Perspectives and the Shift Toward Earlier ADC Integration
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how rapidly evolving guidelines are reshaping treatment pathways by preserving endocrine therapy as a backbone while introducing earlier use of combination regimens and ADCs.
Sequencing Targeted Therapies and Approaches for Genomic Versus Non-Genomic Cases
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how sequencing targeted therapies after CDK4/6 inhibitors differs for patients with actionable mutations versus those without, incorporating evidence for rechallenge and combination strategies.
Introduction and Genomic Testing in Advanced Breast Cancer
ByHeather McArthur, MD, MPH,Sarah Sammons, MD,Ruta Rao, MD,William J. Gradishar, MD,Tiffany Traina, MD, FASCO Panelists discuss how integrating both tissue and liquid genomic testing at diagnosis and progression improves detection of tumor heterogeneity and informs personalized treatment decisions in metastatic breast cancer.
